pharmaceutical investing Verona Pharma plc Operational Update and Financial Results for the First Quarter Ended March 31, 2018
Eloxx Pharmaceuticals Announces FDA Grant of Orphan-Drug Designation for Investigational Drug ELX-02 for Treatment of Cystinosis
pharmaceutical investing Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis
pharmaceutical investing Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis
pharmaceutical investing Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update
pharmaceutical investing Santhera Obtains Worldwide Exclusive License from Polyphor to Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis
pharmaceutical investing Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design
pharmaceutical investing Corbus Gets Patent Covering Use of Anabasum for the Treatment of Rare Fibrotic Diseases
Alvopetro Announces Q3 2026 Dividend of US$0.12 Per Share and Supplementary Information on December 31, 2025 Prospective Resources
Skyharbour Partner Company Purecore Commences Data Compilation and Target Generation at The Yurchison Uranium Property
